Ceftazidime-Avibactam: Indications, Dosing, and Renal Adjustments
Ceftazidime-avibactam 2.5 g IV every 8 hours (infused over 2 hours) is the standard adult dose for carbapenem-resistant Enterobacterales (CRE) infections, with mandatory renal dose adjustments for creatinine clearance ≤50 mL/min and extended 3-hour infusions recommended for severe infections to optimize outcomes. 1
FDA-Approved Indications
Ceftazidime-avibactam is approved for:
- Complicated urinary tract infections (cUTI) including pyelonephritis in adults and pediatric patients ≥3 months 1
- Complicated intra-abdominal infections (cIAI) in combination with metronidazole in adults and pediatric patients ≥3 months 1
- Hospital-acquired pneumonia (HAP) including ventilator-associated pneumonia (VAP) in adults and pediatric patients ≥3 months 1
- Infections due to aerobic Gram-negative organisms in adults and pediatric patients ≥3 months with limited treatment options 1
The drug demonstrates particular utility against KPC-producing and OXA-48-producing CRE, but is inactive against metallo-β-lactamase (MBL) producers unless combined with aztreonam 2, 1.
Standard Adult Dosing Regimens
By Clinical Syndrome (Normal Renal Function)
Bloodstream Infections:
- 2.5 g IV every 8 hours, infused over 3 hours (extended infusion)
- Duration: 7-14 days 1
- The 3-hour infusion is critical—a large Italian study of 577 patients showed prolonged infusion was independently associated with 30-day survival 2
Complicated Urinary Tract Infections:
- 2.5 g IV every 8 hours
- Duration: 5-7 days 1
Complicated Intra-Abdominal Infections:
- 2.5 g IV every 8 hours plus metronidazole 500 mg every 6 hours
- Duration: 5-7 days 1
Hospital-Acquired/Ventilator-Associated Pneumonia:
- 2.5 g IV every 8 hours
- Duration: 10-14 days 1
Renal Dose Adjustments (Adults)
Ceftazidime-avibactam requires dose reduction when CrCL ≤50 mL/min because both components are eliminated almost exclusively by glomerular filtration 3:
| Creatinine Clearance | Recommended Dose | Frequency |
|---|---|---|
| 31-50 mL/min | 1.25 g | Every 8 hours |
| 16-30 mL/min | 0.94 g | Every 12 hours |
| 6-15 mL/min | 0.94 g | Every 24 hours |
| <6 mL/min | 0.94 g | Every 48 hours |
Hemodialysis patients: Give loading dose of 2.5 g, then 0.94 g after each dialysis session 3
CRRT patients: Recent PK/PD data suggest the standard 2.5 g every 8 hours may cause excessive drug exposure and neurotoxicity risk (90% of patients exceeded the 104 mg/L neurotoxicity threshold). Dose reduction is prudent, though specific recommendations require individualized therapeutic drug monitoring 4.
Critical Pitfall: Neurotoxicity Risk
Ceftazidime concentrations >80-104 mg/L are associated with neurotoxicity. This is particularly concerning in patients with renal impairment receiving standard doses 5, 4. Always calculate CrCL and adjust doses accordingly—failure to do so significantly increases seizure risk.
Pediatric Dosing (≥3 months to <18 years)
Standard pediatric dose (normal renal function):
- ≥6 months to <18 years and ≥40 kg: 2.5 g IV every 8 hours
- ≥6 months to <18 years and <40 kg: 50 mg/kg IV every 8 hours (maximum 2.5 g per dose)
- 3 months to <6 months: 40 mg/kg IV every 8 hours 6
Pediatric renal adjustments: Use equivalent dose reductions and interval extensions as adults, normalized to body surface area (CrCL ≤50 mL/min/1.73 m²) 6. The 2023 population PK modeling study confirmed that pediatric patients with renal impairment should receive proportionally adjusted doses matching adult exposure targets 6.
Combination Therapy Considerations
For MBL-Producing CRE (NDM, VIM)
Ceftazidime-avibactam MUST be combined with aztreonam because avibactam does not inhibit metallo-β-lactamases 2, 1. A 2022 prospective study of 102 patients with MBL-producing CRE bacteremia showed the combination significantly reduced 30-day mortality (HR 0.37,95% CI 0.13-0.74) compared to other regimens 2.
Practical dosing for CAZ-AVI + aztreonam:
- Ceftazidime-avibactam 2.5 g IV every 6-8 hours
- Aztreonam 2 g IV every 6-8 hours
- Both infused over 2-3 hours
- Requires harmonization of renal dose adjustments for both drugs 7, 8
Monotherapy vs. Combination for KPC-Producing CRE
Monotherapy is generally sufficient for KPC-producing CRE 2. Five retrospective cohorts totaling 824 patients showed no mortality difference between ceftazidime-avibactam monotherapy versus combination therapy for KPC and OXA-48 producers 2. However, combination with a carbapenem or colistin may be considered if ceftazidime-avibactam resistance emerges during therapy (the "see-saw effect" with KPC-3 variants) 1.
Administration Pearls
- Infusion duration matters: Use 3-hour infusions for severe infections (BSI, pneumonia) to maximize time above MIC 2, 1
- Appropriate renal adjustment is mandatory: This is not optional—the largest real-world study showed proper renal dosing was independently associated with survival 2
- Reconstitution: Each 2.5 g vial contains ceftazidime 2 g + avibactam 0.5 g 3
- Stability: Compatible with most IV solutions; consult package insert for specific compatibility data 3
Treatment Duration by Indication
- cUTI/pyelonephritis: 5-7 days 1
- cIAI: 5-7 days (with source control) 1
- BSI: 7-14 days depending on source control and clinical response 1
- HAP/VAP: 10-14 days 1
Duration should be shortened with rapid source control and clinical improvement, or extended for inadequate source control, immunocompromised status, or slow clinical response 1.
Key Resistance Considerations
Ceftazidime-avibactam resistance can emerge during therapy, particularly with KPC-3-producing K. pneumoniae 1. Risk factors include prior ceftazidime-avibactam exposure and inadequate dosing. When resistance develops, meropenem MICs often decrease back into the susceptible range (the "see-saw effect"), making carbapenem re-challenge a potential salvage option 1.
The drug has NO activity against:
- Metallo-β-lactamases (NDM, VIM, IMP) when used alone
- Most Acinetobacter species
- Most anaerobes (except B. fragilis, C. perfringens, Prevotella, Porphyromonas) 9